Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3M (up 16.6% year over year) with net income of −$32M.
Q3 2025 key financials · XBRL
- Revenue
- $3M
- +16.6% YoY · +64.7% QoQ
- Net income
- −$32M
- −125.2% YoY · −13.2% QoQ
- Operating margin
- -1005.1%
- EPS (diluted)
- −$3.62
- −116.0% YoY · +8.6% QoQ
Source: XBRL data from the Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2025 10-Q on SEC EDGAR. USD.
Tonix Pharmaceuticals Holding Corp. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.29M, up from $2.82M YoY, driven by migraine product demand and additional sales representatives
- Best product Tosymra revenue $708K vs $337K; Zembrace SymTouch $2.58M vs $2.49M
- Operating loss $33.1M vs $15.6M; net loss $32.0M vs $14.2M
- Cash $190.1M; operating cash use $60.2M vs $46.3M; financing provided $155.4M
- Tonmya launch expected before November 2025; additional funding required, with operations funded into first quarter 2027
Risk Factors
- No material changes identified; risks incorporated by reference to December 31, 2024 Form 10-K
- Tonmya commercialization risk from inadequate third-party reimbursement or market acceptance
- Regulatory risk from healthcare legislative or regulatory reform measures
- Competitive risk from existing or newly introduced products targeting the same indication
- Operational risk from manufacturing, marketing, sales, or distribution-channel failures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tonix Pharmaceuticals Holding Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.